Recent performance snapshot

United Therapeutics (UTHR) has drawn attention after a strong past year, with a 1-year total return of 84.8% and a 3-month return of 17.3%. This has prompted closer scrutiny of its current valuation and fundamentals.

The recent 1-day share price return of a 4.6% decline sits against a 90-day share price return of 17.3% and a 1-year total shareholder return of 84.8%. This suggests momentum has been building over a longer horizon despite short-term swings, at a share price of $569.18.

If United Therapeutics has you rethinking where healthcare and AI could intersect, it may be worth scanning for other potential opportunities across 35 healthcare AI stocks

With the stock at $569.18, an intrinsic value estimate suggesting a large discount, and a price target implying further upside, the real question is whether United Therapeutics is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 11.6% Undervalued

With United Therapeutics last closing at $569.18 against a narrative fair value of $644.08, the current price sits below what this widely followed storyline is built around, putting the focus on how its pulmonary and organ platforms could reshape the business over time.

The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine, which can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.

Want the full story behind that valuation gap? The narrative leans on a detailed mix of assumed revenue growth, resilient margins, and a future earnings multiple that has to line up for the math to work.

Result: Fair Value of $644.08 (UNDERVALUED)

However, this hinges on key clinical readouts and heavy R&D spend. Disappointing trial results or high-cost projects that stall could quickly challenge that undervalued story.

Another way to look at value

While the narrative fair value suggests United Therapeutics is 11.6% undervalued, the SWS DCF model goes much further, with an estimated future cash flow value of $1,822.34 per share versus a $569.18 price today. When two methods are this far apart, which one feels more realistic to you?

Next Steps

If this mix of optimism and caution has you on the fence, take time to review the details yourself and form your own view with 3 key rewards

Ready to find your next idea?

If United Therapeutics is on your radar, do not stop there. Your next smart move could be sitting in plain sight among other well screened stocks.

• Target stronger fundamentals by scanning companies filtered for robust finances with the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for potential value opportunities by checking out the 51 high quality undervalued stocks before the crowd pays attention.
• Spot potential future standouts early by reviewing the screener containing 23 high quality undiscovered gems while they still fly under most investors' radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.